60 Degrees Pharmaceuticals Hosts Investor Webinar to Discuss Expansion Plans for Tafenoquine

What's Happening?

60 Degrees Pharmaceuticals, Inc., a company focused on developing medicines for vector-borne diseases, is set to host an investor webinar on October 22, 2025. The event will feature CEO Geoffrey Dow, PhD, who will discuss the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial drug developed in collaboration with the U.S. Army. The company plans to expand FDA approval for tafenoquine to treat babesiosis, a tick-borne illness. Currently, there are no FDA-approved therapies for babesiosis, and the company is conducting two clinical trials with a third planned. Tafenoquine has Orphan Drug status for babesiosis and patent exclusivity for malaria prevention through 2035. The webinar will include a live Q&A session with management.

Why It's Important?

The expansion of tafenoquine's use to treat babesiosis could significantly impact public health, as the disease is reportedly underrepresented in CDC estimates. With no current FDA-approved treatments, 60 Degrees Pharmaceuticals' efforts could fill a critical gap in healthcare. The company's collaboration with the U.S. Army and its strategic partnerships with research organizations in the U.S., Australia, and Singapore highlight its commitment to addressing global health challenges. The potential market expansion for tafenoquine could also enhance the company's commercial footprint and financial performance, benefiting investors and stakeholders.

What's Next?

Following the webinar, 60 Degrees Pharmaceuticals may see increased interest from investors and stakeholders, particularly if the clinical trials for babesiosis show promising results. The company's plans to initiate a third clinical trial could further bolster its position in the pharmaceutical market. Regulatory approval for tafenoquine's new indication would likely lead to expanded distribution and increased revenue. Stakeholders will be watching closely for updates on the clinical trials and any regulatory decisions that could impact the company's growth trajectory.